Global First Approval For Takeda's Dengue Vaccine, In Indonesia
Set To Open Door To Wider Vaccine Use?
Executive Summary
Takeda’s dengue vaccine Qdenga has received its global first approval in Indonesia, as Qdenga, also marking the first time for the firm to market a vaccine outside Japan and potentially paving the way to wider global use of vaccines for the mosquito-borne disease following setbacks for earlier contenders.
You may also be interested in...
Takeda Sees Mainstays Tiding It Over Upcoming Expiries
As Takeda reported what its CEO described as "a remarkable year," the company sees itself as well positioned to ride out the expiries over the next few years of exclusivity for several big-selling products, as it looks to mainstays and more organic growth to tide it over the "temporary headwinds."
Takeda Still Hopeful On Dengue Vaccine Candidate
Takeda says loss of accelerated assessment status at EMA for marketing authorization application for its dengue vaccine candidate TAK-003 “was anticipated as a potential outcome.”
Takeda To Build On COVID-19 Awareness For Its Dengue Vaccine
Takeda’s vaccines chief Rajeev Venkayya tells Scrip about its COVID-19 vaccines partnerships, and how the pandemic can stimulate action against other infectious disease threats such as Dengue.